Regulatory Milestone Achieved for Entry into the European Market

SK Biopharmaceuticals has successfully obtained marketing authorization from the European Medicines Agency (EMA) for Ontozry (cenobamate), its independently developed anticonvulsant. This approval is for use as an adjunctive therapy in adult patients with refractory partial-onset seizures who have not responded adequately to two or more prior antiepileptic drugs. Angelini Pharma, which holds the European distribution rights, will lead the local commercialization efforts. This signifies SK Biopharmaceuticals' successful navigation of regulatory hurdles in the global pharmaceutical market. With this approval, Ontozry has established a solid regulatory foundation for its entry into Europe, the world's second-largest epilepsy market, following its launch in the United States (under the brand name Xcopri).

Clinically Proven Efficacy in Reducing Seizures

The clinical value of Ontozry is supported by compelling data from global Phase 2 and Phase 3 clinical trials, demonstrating significant reductions in seizure frequency and a high rate of seizure-free patients. In the Study 017 maintenance period, the 200mg dose group achieved a median seizure reduction of 55%, and the 400mg dose group also achieved 55%. Notably, 21% of patients in the 400mg group experienced complete seizure remission. Compared to existing standard treatments, which have single-digit seizure remission rates, Ontozry offers a potential game-changer for patients with refractory epilepsy, significantly improving their quality of life. This differentiated efficacy is attributed to cenobamate's dual mechanism of action: positive allosteric modulation of GABAA receptors and blockade of voltage-gated sodium channels.

Angelini Pharma's Commercialization Strategy and Financial Expectations

The European launch of Ontozry will be driven by Angelini Pharma's distribution network and marketing capabilities. In January 2021, Angelini Pharma acquired Arvelle Therapeutics for $960 million, securing full European rights to Ontozry. SK Biopharmaceuticals will receive substantial commercial milestone payments as a result of this approval and is expected to generate ongoing revenue through royalties linked to future European sales. The speed of price negotiations with national health authorities and reimbursement listings will be a key factor in determining the penetration rate in the European market.

Shifting Competitive Landscape in the Global Epilepsy Market

The global epilepsy market is estimated at approximately $8.3 billion annually, with UCB's Vimpat (lacosamide) and Briviact (brivaracetam) holding significant market share. However, Ontozry is poised to rapidly gain market share by leveraging its superior seizure-free rate compared to competing drugs. Even with the impending generic competition following the expiration of Vimpat's patent, Ontozry, with its unique clinical data, is likely to maintain a premium pricing position. In the medium to long term, expansion into pediatric indications and primary generalized tonic-clonic seizures could drive Ontozry's growth into a blockbuster drug with annual sales exceeding $1 billion.